PURPOSE: To test the hypothesis that radiation dose to (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET)-defined active bone marrow (BM(ACT)) subregions is correlated with hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. METHODS AND MATERIALS: The conditions of 26 women with cervical cancer who underwent (18)F-FDG-PET before treatment with concurrent cisplatin and intensity-modulated radiation therapy were analyzed. BM(ACT) was defined as the subregion of total bone marrow (BM(TOT)) with a standardized uptake value (SUV) equal to or above the mean for that individual. Inactive bone marrow (BM(INACT)) was defined as BM(TOT) - BM(ACT). Generalized linear modeling was used to test the correlation between BM(ACT) and BM(INACT) dose-volume metrics and hematologic nadirs, particularly white blood cell count (WBC) and absolute neutrophil count (ANC). RESULTS: Increased BM(ACT) mean dose was significantly associated with decreased log(WBC) nadir (β = -0.04; 95% CI, -0.07 to -0.01; p = 0.009), decreased log(ANC) nadir (β = -0.05; 95% CI, -0.08 to -0.02; p = 0.006), decreased hemoglobin nadir (β = -0.16; 95% CI, -0.27 to -0.05; p = 0.010), and decreased platelet nadir (β = -6.16; 95% CI, -9.37 to -2.96; p < 0.001). By contrast, there was no association between BM(INACT) mean dose and log(WBC) nadir (β = -0.01; 95% CI, -0.06 to 0.05; p = 0.84), log(ANC) nadir (β = -0.03; 95% CI, -0.10 to 0.04; p = 0.40), hemoglobin nadir (β = -0.09; 95% CI, -0.31 to 0.14; p = 0.452), or platelet nadir (β = -3.47; 95% CI, -10.44 to 3.50; p = 0.339). CONCLUSIONS: Irradiation of BM subregions with higher (18)F-FDG-PET activity was associated with hematologic toxicity, supporting the hypothesis that reducing dose to BM(ACT) subregions could mitigate hematologic toxicity. Future investigation should seek to confirm these findings and to identify optimal SUV thresholds to define BM(ACT).
PURPOSE: To test the hypothesis that radiation dose to (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET)-defined active bone marrow (BM(ACT)) subregions is correlated with hematologic toxicity in cervical cancerpatients treated with chemoradiotherapy. METHODS AND MATERIALS: The conditions of 26 women with cervical cancer who underwent (18)F-FDG-PET before treatment with concurrent cisplatin and intensity-modulated radiation therapy were analyzed. BM(ACT) was defined as the subregion of total bone marrow (BM(TOT)) with a standardized uptake value (SUV) equal to or above the mean for that individual. Inactive bone marrow (BM(INACT)) was defined as BM(TOT) - BM(ACT). Generalized linear modeling was used to test the correlation between BM(ACT) and BM(INACT) dose-volume metrics and hematologic nadirs, particularly white blood cell count (WBC) and absolute neutrophil count (ANC). RESULTS: Increased BM(ACT) mean dose was significantly associated with decreased log(WBC) nadir (β = -0.04; 95% CI, -0.07 to -0.01; p = 0.009), decreased log(ANC) nadir (β = -0.05; 95% CI, -0.08 to -0.02; p = 0.006), decreased hemoglobin nadir (β = -0.16; 95% CI, -0.27 to -0.05; p = 0.010), and decreased platelet nadir (β = -6.16; 95% CI, -9.37 to -2.96; p < 0.001). By contrast, there was no association between BM(INACT) mean dose and log(WBC) nadir (β = -0.01; 95% CI, -0.06 to 0.05; p = 0.84), log(ANC) nadir (β = -0.03; 95% CI, -0.10 to 0.04; p = 0.40), hemoglobin nadir (β = -0.09; 95% CI, -0.31 to 0.14; p = 0.452), or platelet nadir (β = -3.47; 95% CI, -10.44 to 3.50; p = 0.339). CONCLUSIONS: Irradiation of BM subregions with higher (18)F-FDG-PET activity was associated with hematologic toxicity, supporting the hypothesis that reducing dose to BM(ACT) subregions could mitigate hematologic toxicity. Future investigation should seek to confirm these findings and to identify optimal SUV thresholds to define BM(ACT).
Authors: Wang Jianyang; Tian Yuan; Tang Yuan; Wang Xin; Li Ning; Ren Hua; Fang Hui; Feng Yanru; Wang Shulian; Song Yongwen; Liu Yueping; Wang Weihu; Li Yexiong; Jin Jing Journal: Radiol Med Date: 2015-11-27 Impact factor: 3.469
Authors: Masashi Yagi; Luke Arentsen; Ryan M Shanley; Clifford J Rosen; Louis S Kidder; Leslie C Sharkey; Douglas Yee; Masahiko Koizumi; Kazuhiko Ogawa; Susanta K Hui Journal: Calcif Tissue Int Date: 2014-02-23 Impact factor: 4.333
Authors: Tahir Yusufaly; Austin Miller; Ana Medina-Palomo; Casey W Williamson; Hannah Nguyen; Jessica Lowenstein; Charles A Leath; Ying Xiao; Kevin L Moore; Katherine M Moxley; Carlos M Chevere-Mourino; Tony Y Eng; Tarrick Zaid; Loren K Mell Journal: Int J Radiat Oncol Biol Phys Date: 2020-07-03 Impact factor: 7.038
Authors: Tim J Kruser; Stephanie R Rice; Kevin P Cleary; Heather M Geye; Wolfgang A Tome; Paul M Harari; Kevin R Kozak Journal: Technol Cancer Res Treat Date: 2013-03-26
Authors: Ruben Carmona; Jakub Pritz; Mark Bydder; Sachin Gulaya; He Zhu; Casey W Williamson; Christian S Welch; Florin Vaida; Graeme Bydder; Loren K Mell Journal: Int J Radiat Oncol Biol Phys Date: 2014-07-08 Impact factor: 7.038
Authors: Taiki Magome; Jerry Froelich; Yutaka Takahashi; Luke Arentsen; Shernan Holtan; Michael R Verneris; Keenan Brown; Akihiro Haga; Keiichi Nakagawa; Jennifer L Holter Chakrabarty; Sebastian Giebel; Jeffrey Wong; Kathryn Dusenbery; Guy Storme; Susanta K Hui Journal: Int J Radiat Oncol Biol Phys Date: 2016-07-06 Impact factor: 7.038
Authors: P Franco; R Ragona; F Arcadipane; M Mistrangelo; P Cassoni; N Rondi; M Morino; P Racca; U Ricardi Journal: Clin Transl Oncol Date: 2016-04-01 Impact factor: 3.405